[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053230":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":74,"collaborators":31,"id":76,"slug":31,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":31,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":59,"whyStopped":31,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Mannkind Corporation","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Nintedanib DPI 4X day","EXPERIMENTAL","Inhalable",[13],"Drug: Nintedanib Dry Powder Inhalation",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo 4X day","PLACEBO_COMPARATOR",[18],"Drug: Placebo",{"label":20,"type":10,"description":11,"interventionNames":21},"Nintedanib 2X day",[13],{"label":23,"type":16,"description":11,"interventionNames":24},"Placebo 2X day",[18],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Nintedanib Dry Powder Inhalation","Nintedanib DPI is a dry powder nintedanib formulation for oral inhalation.",[20,9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Placebo","Placebo oral inhalation powder",[23,15],[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Senior Vice President, Therapeutic Area Head, Orphan Lung Dise, MD","CONTACT","203-796-3407","wfares@mannkindcorp.com",[43,57],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"NOT_YET_RECRUITING","Danbury","Connecticut","06810","United States",{"type":50,"coordinates":51},"Point",[52,53],-73.45401,41.39482,{"lat":53,"lon":52},[56],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Trial Management Group Inc","RECRUITING","Windsor","Ontario","N8X1T3","Canada",{"type":50,"coordinates":65},[66,67],-83.01654,42.30008,{"lat":67,"lon":66},[70],{"name":71,"role":39,"phone":72,"phoneExt":31,"email":73},"Syed Anees","416-929-7717","aneesresearch@yahoo.com",{"type":75,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100053230",false,"NCT07679893","Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Followed by an Open-Label Extension","INFLO-2","Inclusion Criteria:\n\n* 40-80 years old when signing consent and entering screening.\n* Diagnosed with IPF based on current ATS\u002FERS\u002FJRS\u002FALAT guidelines.\n* Either new to treatment or on a stable dose of pirfenidone and\u002For nerandomilast for at least 3 months before screening.\n* Weighs more than 40 kg (88 lb) at screening.\n* Women who can become pregnant:\n* Must have a negative pregnancy test at screening.\n* Must use an approved birth control method from screening until at least 1 month after the last study dose.\n* Men who can father a child and are sexually active with women who can become pregnant:\n* Must use an approved birth control method during treatment and for at least 3 months after the last study dose.\n* Must not donate sperm during treatment and for at least 3 months after the last study dose.\n* Willing to follow all study rules and restrictions.\n* Willing and able to attend study visits and complete study procedures.\n* Able to perform spirometry (lung function testing) as required by the study.\n\nExclusion Criteria:\n\n* Has a lung disease caused by something other than IPF.\n* Has a connective tissue or autoimmune disease (such as lupus, scleroderma, or rheumatoid arthritis).\n* Has another condition that significantly affects breathing.\n* Has serious heart or blood vessel disease.\n* Has a recent or current infection.\n* Was recently hospitalized for COVID-19, an IPF flare-up, or a lung infection.\n* Has a history of asthma (except childhood asthma that has resolved).\n* Has another medical condition or abnormal test result that may affect study participation or safety.\n* Cannot perform high-quality spirometry testing.\n* Has obstructive lung disease.\n* Has abnormal liver function tests.\n* Has moderate to severe liver disease.\n* Has severe kidney disease.\n* Has recently used high-dose steroids or other immune-suppressing medications.\n* Has active cancer or recent cancer treatment.\n* Is on, or expected to be added to, a transplant list.\n* Had major surgery recently or has planned procedures that could interfere with the study.\n* Has had a severe reaction to nintedanib or cannot take nintedanib safely.\n* Has recently used certain medications that may interact with the study drug.\n* Is currently using, or plans to use, prohibited medications during the study.\n* Has recently participated in another clinical trial.\n* Has current alcohol or drug abuse issues.\n* Donated a significant amount of blood recently.\n* Received a live vaccine recently.\n* Currently smokes, recently smoked, or quit smoking less than 1 year ago.\n* Requires more than 6 L\u002Fmin of oxygen while at rest.","ALL","40 Years","80 Years",{"count":87,"type":88},210,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1\u002FFVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.",[94,95],"Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis (IPF)",[97,98,99,100,101],"inhalable treatments","lung scarring","Pulmonary fibrosis","fibrosis","pulmonary","2026-07-09",{"date":104,"type":105},"2026-07-13","ACTUAL",{"date":107,"type":88},"2026-06-30",{"date":109,"type":88},"2028-12",{"name":5,"class":6},2]